Eli Lilly (LLY) Form 4: Director reports 117-share acquisition
Rhea-AI Filing Summary
Gabrielle Sulzberger, a director of Eli Lilly & Co. (LLY), reported acquiring 117 shares of common stock on 08/12/2025 under transaction code P. The reported price was $641.182 per share and her direct holdings after the trade were 2,703.055 shares. The Form 4 was filed by one reporting person.
Positive
- None.
Negative
- None.
Insights
TL;DR Director acquisition of 117 shares at $641.182 increases direct holdings to 2,703.055 shares; transaction appears routine and non-material.
The filing documents a non-derivative acquisition by Gabrielle Sulzberger on 08/12/2025. The transaction is reported under code P with 117 shares acquired at $641.182 per share, raising direct beneficial ownership to 2,703.055 shares. As disclosed, this is a straightforward insider purchase disclosed on Form 4 and does not, by itself, indicate any change in corporate strategy or governance.
TL;DR Routine insider purchase by a director; maintains alignment of management/board with shareholder interests but shows no governance changes.
The report shows Gabrielle Sulzberger, identified as a director, increased her direct holding via a reported acquisition. The transaction is recorded on Form 4 and signed by an authorized representative. The disclosure meets Section 16 reporting requirements and reflects ongoing ownership by a board member; no departures, appointments, or material governance events are reported in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 117 | $641.182 | $75K |
FAQ
Who filed the Form 4 for Eli Lilly (LLY)?
What transaction was reported on the Form 4 for LLY?
When was the transaction dated on the Form 4 for LLY?
AI-generated analysis. How Rhea-AI works. Not financial advice.